Survodutide
AKA BI 456906
GLP-1 and glucagon dual-receptor agonist in trials for obesity and liver disease (MASH).
Caution
Investigational drug, not approved. Research/clinical-trial use only.
Overview
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors from Boehringer Ingelheim and Zealand Pharma. It is being developed for weight loss and for metabolic dysfunction-associated steatohepatitis (MASH).
Survodutide is an investigational dual agonist that activates both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. The GLP-1 side handles appetite suppression and glucose control; the glucagon side increases energy expenditure and, importantly, drives reduction of fat in the liver. That combination makes it a dual-purpose candidate for both obesity and liver disease.
Its most closely watched indication is metabolic dysfunction-associated steatohepatitis (MASH) — the serious, progressive form of fatty liver disease. Phase II data has shown significant weight loss along with improvement in liver fibrosis, a notoriously hard endpoint to move. Phase III trials are ongoing, and it is not yet approved.
Mechanism of Action
Activates GLP-1 receptors (appetite and glucose control) and glucagon receptors (energy expenditure and hepatic fat reduction), combining satiety with increased metabolic rate.
Use Cases
- Weight management (investigational)
- MASH / fatty liver disease
- Metabolic health
Research Summary
Phase II trials show significant weight loss and improvement of liver fibrosis in MASH. Phase III is ongoing. Not yet approved.
Explain It Like I'm 5 Years Old
This medicine pushes two buttons at once. One button (GLP-1) makes you less hungry and helps control blood sugar. The second button (glucagon) makes your body burn a bit more energy and, in particular, helps clean fat out of the liver. So it is being tested both to help people lose weight and to fix a sick, fatty liver.
How the Gym Bros Are Using It
A next-gen GLP-1/glucagon dual agonist that is on the radar mostly for weight loss and, uniquely, liver-fat reduction. The glucagon arm bumping energy expenditure is the interesting wrinkle versus a pure GLP-1. Still investigational and trial-only, so this is future-watch territory rather than a current protocol — but it is one of the names to know in the pipeline alongside retatrutide.
Investigational; weekly subcutaneous dosing in trials. Not a medical recommendation.
Administration
Research Chemical
Investigational drug, not approved. Research/clinical-trial use only.
Verified Sources for Survodutide
Browse all →
Vyal Labs
Sheridan, WY
LabFirst Peptides
Santa Ana, CA
OMNI Peptides
Las Vegas, NV
Elite Synthetics
Huntington Beach, CA
AminoVault
Los Angeles, CA
Apex Pharma
Newcastle ,
UPGUYS Health
Etobicoke, ON
Skin Deva
Lomita, CA
Nextgenpeps
San Diego, CA
Fragranci
Lomita, CA
Titan Peptide Lab
Online, US
Creative Bioarray DDA
New York, NY